Related Experiment Video
Updated: Mar 16, 2026
08:10
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
8.4K
Fenofibrate and Diabetic Retinopathy.
Jared E Knickelbein1, Akshar B Abbott1, Emily Y Chew2,3
1National Eye Institute, National Institutes of Health, 10 Center Dr, 10/10D45, Bethesda, MD, 20892, USA.
Current Diabetes Reports
|August 16, 2016
Summary
Diabetic retinopathy is a leading cause of blindness. Fenofibrate therapy shows promise in slowing its progression, offering a new strategy to combat this diabetes complication.
Area of Science:
- Ophthalmology
- Endocrinology
- Diabetology
Background:
- Diabetic retinopathy is a major cause of blindness in working-aged adults.
- Hyperglycemia and hypertension control can mitigate diabetic retinopathy incidence and progression.
- The role of dyslipidemia and statins in diabetic retinopathy remains unclear.
Purpose of the Study:
- To evaluate the efficacy of fenofibrate in managing diabetic retinopathy progression.
Main Methods:
- Review of recent randomized clinical trials on fenofibrate therapy for diabetic retinopathy.
Main Results:
- Systemic fenofibrate therapy demonstrated significant benefits in reducing diabetic retinopathy progression.
- These benefits were observed independently of the patients' serum lipid levels.
Conclusions:
- Fenofibrate represents a potential therapeutic strategy to slow diabetic retinopathy progression.
- This approach could alleviate the public health burden associated with sight-threatening diabetic complications.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
01:11Renal Failure: Dose Adjustments
565
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
565
01:15Diabetes: Management and Pharmacotherapy
1.3K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
770
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
770